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Peste des petits ruminants (PPR) and foot-and-mouth disease (FMD) are both highly contagious diseases of small domestic
and wild ruminants caused by the PPR virus (PPRV) and the FMD virus (FMDV). In this study, a recombinant PPRV expressing
the FMDV VP1 gene (rPPRV/VP1) was generated and FMDV VP1 expression did not impair replication of the recombinant
virus in vitro and immunogenicity in inducing neutralizing antibody against PPR in goats. Vaccination with one dose of
rPPRV/VP1 induced FMDV neutralizing antibody in goats and protected them from challenge with virulent FMDV.
Our results suggest that the recombinant PPRV expressing the FMDV VP1 protein is a potential dual live vectored
vaccine against PPRV and FMDV.Introduction
Foot and mouth disease (FMD) is a severe, highly conta-
gious, clinically acute, economically devastating viral dis-
ease of wild and domestic cloven-hoofed animals, such as
cattle, pigs, goats, and sheep. It is caused by foot and mouth
disease virus (FMDV), a member of the family Picornaviri-
dae, genus Aphthovirus. FMDV contains a 7–8-kb, single-
stranded, positive-sense RNA genome that encodes a single
polyprotein, which is cleaved into four structural proteins
(viral protein (VP)4, VP2, VP3, and VP1) and eight non-
structural proteins (L, 2A, 2B, 2C, 3A, 3B, 3C, and 3D poly-
merase). The genome is enclosed within a nonglycosylated,
icosahedral capsid comprising 60 copies each of VP1–4 [1].
Seven immunologically distinct serotypes (A, O, C, SAT1,
SAT2, SAT3, and Asia1) were identified on the basis of a
VP1 coding region sequence. VP1 is exposed on the surface
of viral particles and is the main antigen to elicit a neutral-
izing antibody response [2,3]. Currently, FMD is mainly
controlled by inactivated virus vaccines, which provide only* Correspondence: xiachun@cau.edu.cn; buzhigao@caas.cn
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reproduction in any medium, provided the orshort-term protection (4–6 months), and may create carrier
animals [4,5].
Peste des petits ruminants (PPR) is a highly contagious
disease of domestic and wild small ruminants caused by
the peste des petits ruminants virus (PPRV) and is re-
sponsible for serious socioeconomic problems in some
of the poorest developing countries [6-8]. PPR was first
reported in the Ivory Coast in 1942 and later found in
the Middle and Near East, southwest and central Asia
[9-12], and recently in China [13]. PPRV, which is a
member of the genusMorbillivirus belonging to the family
Paramyxoviridae [14], contains a linear, non-segmented,
single-stranded, negative-sense, 15948-bp, RNA genome,
which encodes six structural proteins, nucleocapsid (N),
phosphoprotein (P), matrix (M), fusion (F), hemagglutinin
(H) and polymerase (L), and two nonstructural proteins, C
and V that are genomically encoded in the order of 3′-N-
P/C/V-M-F-H-L-5′ [15,16]. An attenuated PPRV strain,
Nigeria/75/1, derived from serial-passage in Vero cells, has
been widely used as a safe and efficacious live vaccine to
control PPR infections [17].
Several studies have indicated that recombinant para-
myxoviruses are effective and genetically stable vectors
with many advantages. It is easy to generate recombin-
ant paramyxovirus vectored vaccine candidates using re-
verse genetic techniques, the recombinant vaccine could. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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it could potentially be used as a DIVA (Differentiating
Infected from Vaccinated Animals) vaccine [18-20]. Rinder-
pest virus, which is also a member of the genus Morbilli-
virus, has been used as vector expressing FMDV epitopes
[21]. In our previous study [22], reverse genetics for PPRV
was successfully established, providing a novel method to
develop bivalent, live-vectored vaccines against PPRV and
other important viral diseases in goats and sheep, such as
FMDV, Rift valley fever, and bluetongue virus. In this study,
we constructed a recombinant PPRV expressing FMDV




Live PPRV attenuated vaccine strain Nigeria 75/1 (N75/1)
was obtained from the China Institute of Veterinary Drug
Control (Beijing, China) who imported it from The Pirb-
right Institute (Pirbright, United Kingdom). BHK-21 cells
(ATCC no.: CCL-10; The American Type Culture Collec-
tion, Manassas, VA, USA) and Vero cells (ATCC no.:
CCL-81) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Carlsbad, CA, USA) containing
10% fetal bovine serum (FBS) (Gibco). N75/1 and rescued
recombinant PPRV were propagated and titrated in Vero
cells cultured in DMEM containing 2% FBS. FMDV strain
Asia1/JSL/GSZY/06 (JSL/06) was conserved in Baoshan
Bio-pharmaceutical Factory of China Animal Husbandry
Industrial Co., Ltd. (Baoshan, China) and propagated in
2–7-day old suckling mice. A 50% goat infective dose was
determined in goats [23].
Plasmid construction and rescue of recombinant viruses
The plasmid pN75/1 insertion (Figure 1A) contained a full-
length N75/1 cDNA sequence flanked with a hammerhead
ribozyme sequence (HamRz), hepatitis delta virus ribozymeFigure 1 Plasmid construction for recombinant PPRV rescue. (A) pN75/1-i
gene start (GS) sequence, Not I and Pme I sites, gene end (GE) sequence, and C
cDNA. (B) The VP1 ORF with a Kozak sequence at the 5' end of the ORF was insequence, and insertion sequence (a gene start sequence,
Not I and Pme I restriction sites, a gene end sequence, and
an intergenic CTT trinucleotide), and helper plasmids
(pCA-N, pCA-P and pCA-L) were constructed as previ-
ously described [22]. The cDNA for the open reading frame
(ORF) of the FMDV VP1 (Asia1) protein was synthesized
according to a published sequence (GenBank accession no.:
GU931682). The Not I restriction sequence (bold), Kozak
sequence (gccgccacc, low case and italic) and the ATG ini-
tiation codon were introduced at the 5′ end of the cDNA
encoding VP1; the TAA termination codon and Pme I re-
striction sequence (uppercase and italic) were introduced at
the 3′ end of the cDNA encoding VP1, and the final DNA
fragment (GCGGCCGCgccgccaccATGactaccaccact……cctg
agaaacagTAAGTTTAAAC) was treated with Not I and
PmeI and inserted into the plasmid pN75/1 insertion be-
tween Not I and PmeI sites. The resulting pN75/1-VP1
plasmid was used to rescue the recombinant virus. The
method to rescue the recombinant virus was described
previously [22]. Briefly, 90% confluent Vero cells in one
well of a 6-well plate were transfected with the plasmids
pCA-N (2 μg), pCA-P (1 μg), and pCA-L (1 μg) together
with 4 μg of pN75/1-VP1. Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA) was used for transfection
following the manufacturers’ instructions. After 7–9 days
of incubation at 37 °C, the cells and supernatants were
collected and freeze-thawed twice and then passaged in
fresh cells to propagate the rescued viruses. Supernatants
from cytopathic effect-positive wells were used to propa-
gate viral stocks in Vero cells. The complete genomic
sequences of the rescued viruses were confirmed by se-
quencing. The rescued virus was named rPPRV/VP1.
Immunofluorescence assay (IFA)
Vero cells grown in 24-well plates were infected with
N75/1 or rPPRV/VP1 at a multiplicity of infection (MOI)
of 0.1 and incubated for 3 days. The cells were fixed withnsertion was constructed previously [22] through insertion of a morbillivirus
TT intergenic trinucleotides between the P and M genes of genomic PPRV
serted into plasmid pN75/1-insertion to generate plasmid pN75/1-VP1.
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stained with anti-N75/1 mouse serum [24,25] or anti-
FMDV VP1 rabbit serum (Asia1 type) [26] followed by
tetramethyl rhodamine isothiocyanate-labeled goat anti-
mouse immunoglobulin IgG (Sigma-Aldrich, St. Louis,
MO, USA) or fluorescein isothiocyanate-labeled goat anti-
rabbit IgG (Sigma). Mock-infected cells were used as con-
trols. The fluorescence was observed using an inverted
fluorescence microscope (Carl Zeiss AG, Oberkochen,
Germany).
Western blotting
Vero cells were infected with N75/1 or rPPRV/VP1 at an
MOI of 0.1 and incubated for 5 days, and BHK-21 cells
were infected with FMDV JSL/06 at an MOI of 0.1 and in-
cubated for 12–16 h. The N75/1 and rPPRV/VP1 particles
were both purified by sucrose gradient centrifugation with
60%, 40% and 20% density (140 000 g). The cell extracts of
Vero and BHK-21 and purified virus particles were ana-
lyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and blotted onto a nitrocellulose
membrane, which was then incubated with anti- FMDV-
VP1 rabbit serum (Asia1 type) [26] or anti-PPRV-N rabbit
serum produced through immunization with purified
recombinant PPRV N expressed in E.coli as the first
antibody, and horseradish peroxidase-conjugated goat
anti-rabbit IgG (Sigma-Aldrich) as the secondary anti-
body. Immunostained proteins were visualized with
3,3′-diaminobenzidine reagent. Mock-infected Vero cells
and mock-infected BHK-21 cells were used as controls.
Vaccination and viral neutralizing antibody (NA) assay
One-year-old black goats (a local breed of Yunna Prov-
ince, China) without neutralizing antibodies to FMDV
(titre < 8) and PPRV (titre < 5) were immunized by intra-
muscular injection at the neck with a 50% tissue culture
infective dose (TCID50) of 6 × 10
6 rPPRV/VP1 or N75/1.
Sera were collected at 14, 21, 28, and 40 days post-
vaccination for NA assays. The NA to PPRV N75/1 were
titrated in Vero cells as described previously [22,24] and
the NA to FMDV JSL/06 was titrated in BHK-21 cells
following the protocol recommended by the World
Organization for Animal Health (Office International
des Epizooties) [23]. Antibody titers were expressed as
the reciprocal of the final dilution of serum in the
serum/virus mixture which neutralized an estimated
100 TCID50 of virus at the 50% end-point [27].
Challenge study
Goats vaccinated with N75/1 or rPPRV/VP1 were trans-
ferred from a normal sheepfold to a level 3 animal facility,
where the animals were acclimated for 1 day before viral
challenge. Each goat was challenged with virulent FMDV
JSL/06 at 40 days post-vaccination by two intradermalinjections to the tongue (0.1 mL at each point; a total of
1000 goat infectious dose 50 of FMDV for each goat). The
animals were observed for 14 days post-challenge. Rectal
temperature (°C) was measured daily and heparinized
blood and oropharyngeal swabs were collected at different
days for FMDV detection by inoculation of BHK-21 cells
[28]. Simultaneously, lesions and clinical signs were ob-
served and evaluated daily and scored as follows:
0: no water vacuole or ulceration appeared.
1: a water vacuole or ulceration was only found at the
injection point.
2: one water vacuole or ulceration was found on the
tongue surface, rhinarium, gingiva, or lips, but not at
the injection point.
3: two or more water vacuoles or ulcerations were
found on the tongue surface, rhinarium, gingiva, or
lips, but not at the injection point, or water vacuoles
or ulcerations were found at one ungula.
4: two or more water vacuoles or ulcerations were
found on the tongue surface, rhinarium, gingiva, or
lips, but not at the injection point, while water
vacuoles or ulcerations were found at one or more
ungulas.
Statistical analysis
Statistical analyses were performed by two-way analysis
of variance (ANOVA) or t-tests using GraphPad Prism
statistical software (GraphPad Software, Inc., La Jolla,
CA, USA). A probability (p) value < 0.05 was considered sta-
tistically significant, and < 0.01 statistically very significant.
Results
Generation of recombinant PPRV expressing FMDV VP1
To construct a recombinant PPRV expressing the FMDV
VP1 protein (rPPRV/VP1), the FMDV VP1 gene was
inserted in the genome cDNA of PPRV N75/1 (Figure 1A)
between the P and M genes (Figure 1B). VP1 gene inser-
tion in the genome of rescued recombinant virus rPPRV/
VP1 was confirmed by reverse transcriptase polymerase
chain reaction (RT-PCR) (data not shown) FMDV VP1 ex-
pression in rPPRV/VP1-infected Vero cells was confirmed
by IFA. Both rPPRV/VP1- and N75/1-infected Vero cells
were positive to anti-N75/1 mouse serum [24,25] by IFA
(Figure 2A). rPPRV/VP1-infected Vero cells were positive,
while N75/1-infected Vero cells were negative to rabbit
serum anti-FMDV(Asia1 type) VP1 (Figure 2A). A 28-kDa
band representing the FMDV VP1 protein was detected
by western blotting with rabbit serum anti-FMDV(Asia1
type) VP1 in rPPRV/VP1-infected Vero cells and JSL/06-
infected BHK-21 cells, but not in mock-infected Vero
cells, N75/1-infected Vero cells, mock infected-BHK-21
cells, purified rPPRV/VP1 particles and N75/1 particles
(Figure 2B). At the same time, a 58-kDa band representing
Figure 2 VP1 protein replication and expression of rPPRV/VP1 in Vero cells. (A) Cells infected with rPPRV/VP1, N75/1, or mock-infected were
fixed and labeled with anti-N75/1 mouse serum for the presence of PPRV protein (red) or anti-FMDV VP1 (Asia-I type) rabbit serum for the presence of
the VP1 protein (green). (B) The N75/1 and rPPRV/VP1 particles were respectively purified by sucrose gradient centrifugation with 60%, 40%
and 20% density (140 000 g). Lysates of N75/1- or rPPRV/VP1-infected Vero cells, lysates of FMDV JSL/06-infected Vero cells, N75/1 particles and
rPPRV/VP1 particles were respectively probed by SDS-PAGE and western blotting using anti-FMDV VP1 (Asia-I type) rabbit serum and anti-PPRV-N rabbit
serum respectively. Mock-infected Vero and BHK-21 cells were used as controls.
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PPRV N in rPPRV/VP1-infected vero cells, N75/1-in-
fected Vero cells, purified N75/1 particles and rPPRV/
VP1 particles, but not in JSL/06-infected BHK-21 cells,
mock-infected-Vero cells and mock-infected-BHK-21
cells.
To determine whether the foreign gene insertion af-
fected the replicative ability of the vector virus, growth
curves for rPPRV/VP1- and N75/1-infected Vero cells
were determined and compared. The TCID50 was quan-
titated using previously described methods [29]. The re-
sults show no significant differences in growth titer at
different times post-infection between the two viruses
(Figure 3). The genetic stability of the FMDV VP1 gene
within rPPRV/VP1 was assessed by serially passaging the
virus for 10 times in Vero cells. After 10 passages, the pres-
ence of a genomic FMDV VP1 sequence was confirmed by
RT-PCR and genome sequencing (data not shown). FMDV
VP1 expression in rPPRV/VP1- infected Vero cells was
confirmed by IFA and western blotting (data not shown).
rPPRV/VP1 induced FMDV and PPRV NA in goats
To evaluate the immunogenicity of the recombinant virus,
sera were collected from six rPPRV/VP1-vaccinated goatsand four N75/1-vaccinated goats at 14, 21, 28, and 40 days
post-vaccination and subjected to the NA assay for FMDV
and PPRV. As shown in Figure 4A, all animals underwent
serum conversion to PPRV (NA titer ≥ 10) by 14 days
post-vaccination and PPRV NA titers gradually increased
until 40 days post-vaccination. The NA titer to PPRV
ranged from 500 to 800 and 500 to 1100 at 28 and 40 days
post-vaccination, respectively. There was no statistically
significant difference in PPRV VN titers between rPPRV/
VP1-vaccinated goats and N75/1-vaccinated goats at dif-
ferent days post-vaccination (p > 0.05). rPPRV/VP1 also
induced significant FMDV-specific NA responses. At
14 days post-vaccination, five of six animals vaccinated
with rPPRV/VP1 showed FMDV VN titers ≥ 8. After-
ward, FMDV NA titers continually increased. At post-
vaccination days 28 and 40, FMDV NA titers in all six
animals were 11–28 and 14–34, respectively. As the
control, all four N75/1-vaccinated animals showed post-
vaccination FMDV NA titers of < 8 (Figure 4B). There was
a statistically significant difference in FMDV VN titers be-
tween rPPRV/VP1- and N75/1-vaccinated goats at differ-
ent days post-vaccination (**, p < 0.01). The temperature
of all the animals inoculated with rPPRV/VP1 or N75/1
remained normal after vaccination.























Figure 3 Growth of rescued viruses in Vero cells. The viral titers
in rPPRV/VP1- or N75/1-infected Vero cells were measured at
different days post infection.
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Figure 4 Viral NA responses elicited by rPPRV/VP1 and N75/1 in goat
intramuscular injection with rPPRV/VP1 and four goats (nos. 361, 28, 32 and
were collected at 14, 21, 28, and 40 days post-inoculation and were tittered
two-way ANOVA method using the GraphPad Prism statistical software (**,
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To determine whether rPPRV/VP1 vaccination provided
protective immunity against FMDV, the above six
rPPRV/VP1-vaccinated goats and four N75/1-vaccinated
goats were challenged with the virulent FMDV JSL/06.
In the rPPRV/VP1-vaccinated group, no animal showed
a notable change in body temperature after challenge. In
contrast, all animals in the N75/1-vaccinated group de-
veloped fever by 2–4 days post-challenge (data not
shown). Other than the FMDV inoculation point of one
animal, no lesion was found on the oral mucosa or
tongue surface in any rPPRV/VP1-infected animals post-
challenge. However, vacuoles and/or ulcerated lesions
were found in all N75/1-vaccinated animals post-challenge.
Other than the FMDV inoculation points, water vacuoles
or ulcerations were found on the tongue surface, gingiva,
lips, and/or ungula of all control animals at different times
2–9 days post-challenge (data of photos were not shown).
The severity of the lesions in each animal was quantitated
using a scoring system based on clinical observation as de-
scribed in the Material and methods section (Figure 5),
which shows significant statistical differences in lesion
scores between rPPRV/VP1- and N75/1-vaccinated ani-
mals (p < 0.01). Heparinized blood and oropharyngeal swab
















s. Six goats (nos. 18, 20, 22, 25, 26, and 29) were inoculated by
35) were inoculated by intramuscular injection with N75/1. The sera
for PPRV NA (A) and FMDV NA (B). The data were analyzed by the
p < 0.01).
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Figure 5 Clinical scoring post-challenge with virulent FMDV. Clinical signs of FMD rPPRV/VP1-inoculated goat (nos. 18, 20, 22, 25, 26, and 29)
(A) and N75/1 –inoculated goat (nos. 361, 28, 32, and 35) (B) were observed from 2 to 10 days post challenge with FMDV JSL/06, and the clinical
signs were scored as described in the Material and methods. Statistical differences were evaluated between two groups by the t-test method
using GraphPad Prism statistical software, and the result showed the p < 0.01.
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nated animals, FMDV was recovered from the blood sam-
ples of 1–2 animals and from the oropharyngeal swabs of
1–3 animals at different detection times. However, FMDV
was recovered from blood samples and oropharyngeal
swabs of all four N75/1-vaccinated animals at different
detection times (Figure 6). The results indicate that
rPPRV/VP1 provided significant protection against chal-
lenge of virulent FMDV in goats.
Discussion
In the present study, we generated the recombinant
PPRV vaccine strain N75/1, which expressed the FMDV
VP1 protein. This recombinant virus, rPPRV/VP1, in-
duced 20–40 NA titer against FMDV and a comparable
PPRV NA titer to that induced by N75/1 in goats. More-
over, rPPRV/VP1 provided significant protective immun-
ity against FMDV challenge in goats. Our results suggestthat rPPRV/VP1 is a potential dual, live-vectored vaccine
against PPRV and FMDV.
The synthesis of VP1 gene was based on the sequence
of FMDV isolate JSL/06 (GenBank accession no.: GU
931682). The FMDV JSL/06 had been adapted in BHK-
21 cells and is currently used as a master seed to manu-
facture inactivated vaccine for the controlling of FMDV
Asia 1 in china. We sequenced the vp1 gene of the JSL/
06 vaccine master seed and the JSL/06 challenge virus
stock. There is no amino acid difference of VP1 between
the vaccine seed and the challenge stock, and only one
amino acid difference between the synthesized VP1 and
that of the vaccine seed or the challenge stock.
We employed PPRV N75/1 as a live vaccine vector be-
cause it was shown to be highly immunogenic and in-
duced a prolonged high level of PPRV NA in goats and
sheep [8,17]. The rPPRV/VP1 induced an NA titer against
PPRV that was comparable to that of N75/1 in goats and
Figure 6 Virusisolation post challenge. Heparinized blood (A) and oropharyngeal swabs (B) for FMDV isolation were respectively collected
from six individual rPPRV/VP1-inoculated goats and four individual N75/1-inoculated goats at 2, 4, 7, and 9 days post challenge with FMDV JSL/06.
Viruses were isolated by inoculation of BHK-21 cell culture as described in the Material and methods.
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also showed a similar growth titer to the parent virus in
Vero cells, which was different from that in a previous re-
port regarding a recombinant rinderpest virus expressing
partial sequences of the FMDV capsid VP1 protein [21].
A previous study had described that recombinant RPV
expressing partial sequences of the FMDV capsid VP1
protein could not induce detectable neutralizing anti-
body against FMDV and provide poor protection against
FMDV challenge [21]. For this reason, we vaccinated an-
imals with a higher dosage (6 × 106 TCID50) and got im-
proved results in neutralizing antibody response and
protection efficacy. Even though this dosage is too high
for future field application, our study demonstrates that
the strategy of PPRV vectored VP1 vaccine successfully
works to induce detectable FMDV neutralizing antibody
and provides significant protection against FMDV chal-
lenge, because the same antigen in a different animal
species or with a different expression vector may result
in a significantly different magnitude of immune response.
In addition, the form of antigen expression might sig-
nificantly impact the immune response; cytoplasmi-
cally expressed antigens generally have a bias towards
presentation through the MHC-I pathway and there-
fore to induce a CD8+ T cell-mediated response. Se-
creted or cell membrane displayed antigen may induce
more humoral immunity. In future studies, we will try
to generate recombinant PPRV expressing the secreted
VP1 or entire P1 and hope to get better neutralizing anti-
body responses with relative lower dosage. We will also
try to test if repeat lower dose or combination use with
whole virus inactivated vaccine (priming-boost) could im-
prove antibody response and protective efficacy.Compared to inactivated whole viral vaccine (FMDV
NA titer is around 100) [30], rPPRV/VP1 elicited a rela-
tively low level of FMDV NA (titer < 40) in goats, but
provided significant protection from challenge of viru-
lent FMDV; however, we can also get better immune ef-
fect through two dose vaccination, which could greatly
increase the neutralizing antibody titer according to our
previous study results [19,24,31]. Although the correl-
ation between FMDV NA titer and protective efficacy in
cattle has been well established [32-34], previous studies
have shown that the protection against FMD is related
not only to humoral immunity, but also to cellular im-
munity [35-37]. Previous studies have also shown that
swine immunized with recombinant adenovirus express-
ing FMDV VP1 were completely protected against viru-
lent FMDV challenge, even though the NA (titer < 40)
induced by recombinant adenovirus expressing FMDV
VP1 was significantly lower than that in swine inocu-
lated with inactivated FMD vaccine [38,39]. Also, other
reports showed that swine or cattle immunized with
adenovirus expressing the FMDV P1 protein were pro-
tected against virulent FMDV challenge at post-vaccination
day 7, although an NA titer was undetectable [28,40]. Al-
though rPPRV/VP1 provided significant clinical protection,
FMDV was still detected in blood samples or oropharyn-
geal swabs from partially immunized goats. Similar results
were also observed in other studies with inactivated vac-
cines [4,41]. These results suggest that rPPRV/VP1 has a
potential value for future application. In many countries,
goats and sheep develop PPR, which results in huge eco-
nomic losses and also presents a risk factor for FMD. The
use of the live PPRV vaccine as a vector to develop recom-
binant vaccines against FMDV can control these two
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clinical protection and probably decreases the FMDV
transmission among goats or sheep.
To rapidly respond against future potential outbreaks,
effective and emergent vaccinations should be developed
as soon as possible. Currently, widely used inactivated
whole viral FMD vaccine usually requires 7–10 days to
develop protective immunity and induces only a short
protective period [4,5,30]. A priming-boost regime pre-
sents an option to generate a rapid immune response
and long-lasting protection. However, two doses of vac-
cination increases vaccination and labor costs. Also, the
cost is increased because the inactivated FMD vaccine
must be manufactured in a high-level biosafety facility.
Using a PPRV vectored vaccine can prime the immune
response to FMDV and may induce a long-lasting pro-
tection against FMD and PPR without the need for mul-
tiple doses of inactivated FMDV vaccine, thereby limiting
the costs.
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